Biopsys Medical Inc.: The Irvine developer and...

Biopsys Medical Inc.: The Irvine developer and manufacturer of products for the diagnosis and management of breast cancer reported a larger net loss in the fiscal year ended June 30. The company said it lost $3.5 million, or 43 cents a share, compared with a net loss of $2.5 million, or 55 cents a share, for the prior year. Sales rose to $3.5 million from $80,000. The company posted a fourth-quarter net loss of $922,000, or 10 cents a share, compared with a net loss of $853,000, or 19 cents a share, for the comparable period of the previous year. Sales increased to $1.7 million from $80,000.

The company, which had its initial public offering on May 1, also unveiled two new products to augment its Mammotome system for minimally invasive breast biopsies.

Biopsys said these products, the new 11-gauge Mammotome probe and MicroMark Clip, will enable physicians to take larger breast biopsy tissue samples and mark the biopsy site for subsequent follow-up.